Session Chair Profile
MBA, President and CEO, MolecularMD
Biography
Mr. Snyder has been at MolecularMD since its inception in 2006 and assumed the role of President and CEO in 2014. With over 17 years of experience in the life science research and diagnostic fields, Mr. Snyder has worked extensively in supporting new product introductions and rapid market adoption for novel proteomic and genomic technologies. He received a BA from the University of Virginia and an MBA from the College of William and Mary.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: A tremendous amount of work and effort is put into FDA approval of a drug, yet often the necessary accompanying diagnostics are not in place to meet the needs in a timely fashion. Upstream processes, such as tighter collaborations between pharma and diagnostics companies, more robust and earlier assay development, better transition of translational insight into clinical applications, or clinical trial design itself need to be optimized. This session’s dialogue will focus on these aspects and how a critical diagnostics component can be optimally integrated into a commercial strategy to create a more efficient and successful approval and commercialization process.
